Evidence map›Paper›PMID 37007048›Full record

ArticleFrontiers in pharmacology2023

Investigating the effect of dehydromiltirone on septic AKI using a network pharmacology method, molecular docking, and experimental validation.

Sijia Chen, Yanzhe Wang, Yuyuan Liu, Linnan Bai, Fengqin Li, Yue Wu, Xinmiao Xie, Nan Zhang, Chuchu Zeng, Ling Zhang and 1 more

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sijia ChenDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yanzhe WangDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuyuan LiuDepartment of Nephrology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, China.
Linnan BaiDepartment of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Fengqin LiDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yue WuDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xinmiao XieDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nan ZhangDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chuchu ZengDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Ling ZhangDepartment of Obstetrics and Gynecology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Xiaoxia WangDepartment of Nephrology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Jiao Tong University · CNSir Run Run Shaw Hospital · CNSuzhou Municipal Hospital · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury (AKI) is a severe and frequent complication of sepsis that occurs in intensive care units with inflammation and rapid decline in renal function as the main pathological features. Systemic inflammation, microvascular dysfunction, and tubule injury are the main causes of sepsis-induced AKI (SI-AKI). The high prevalence and death rate from SI-AKI is a great challenge for clinical treatment worldwide. However, in addition to hemodialysis, there is no effective drug to improve renal tissue damage and alleviate the decline in kidney function. We conducted a network pharmacological analysis of

Indexed as

apoptosisCOX2dehydromiltironeinflammatorymitochondrial dysfunctionnetwork pharmacologyseptic AKI

Identifiers

PMID37007048
PMCPMC10050741
OpenAlexW4324377014

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read37
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.